REDWOOD CITY, Calif., Dec. 01, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be participating in a fireside chat at the BMO Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 1:30 p.m. EST being held in New York, NY.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar), CHS-0214 (etanercept biosimilar), and CHS-3351 (ranibizumab biosimilar) as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



